(AIRS) Airsculpt Technologies - Overview
Sector: Healthcare | Industry: Medical Care Facilities | Exchange: NASDAQ (USA) | Market Cap: 376m USD | Total Return: 23.4% in 12m
Avg Turnover: 5.29M
Qual. Beats: 0
Rev. Trend: -86.6%
Qual. Beats: 0
Warnings
Share dilution 16.9% YoY
High Debt/EBITDA (15.7) with thin interest coverage (-1.3)
Interest Coverage Ratio -1.3 is critical
Altman Z'' -1.75 < 1.0 - financial distress zone
Tailwinds
Rs Leader
AirSculpt Technologies, Inc. (AIRS) is a specialized healthcare provider focused on minimally invasive body contouring and fat transfer procedures. Operating primarily in the United States and Canada, the company utilizes proprietary technology to perform fat removal and skin tightening without the use of general anesthesia or needles. Its service portfolio includes specific treatments such as AirSculpt+, AirSculpt Smooth, and various fat transfer enhancements for the breasts, hips, and buttocks.
The company operates within the elective aesthetic surgery sector, a business model characterized by cash-pay revenue streams that bypass traditional insurance reimbursement complexities. Unlike traditional liposuction, AIRS centers focus on awake procedures, which typically reduce facility overhead and patient recovery times. Investors looking for deeper insights into these operational metrics may find ValueRays analytical tools useful for further due diligence. Headquartered in Miami Beach, Florida, the company manages a network of specialized centers dedicated exclusively to its branded body sculpting techniques.
- New center openings and geographic footprint expansion drive top-line revenue growth
- Discretionary consumer spending levels dictate demand for elective body contouring procedures
- Surgeon recruitment and retention costs impact operating margins and facility scalability
- Shifts in weight loss drug popularity influence demand for aesthetic fat removal
- Regulatory compliance and medical licensing standards affect clinic operational continuity
| Net Income: -11.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 6.32 > 1.0 |
| NWC/Revenue: -5.37% < 20% (prev -6.68%; Δ 1.31% < -1%) |
| CFO/TA 0.04 > 3% & CFO 7.50m > Net Income -11.2m |
| Net Debt (80.5m) to EBITDA (5.14m): 15.67 < 3 |
| Current Ratio: 0.75 > 1.5 & < 3 |
| Outstanding Shares: last quarter (69.5m) vs 12m ago 18.66% < -2% |
| Gross Margin: 60.58% > 18% (prev 0.64%; Δ 5.99k% > 0.5%) |
| Asset Turnover: 76.83% > 50% (prev 84.67%; Δ -7.84% > 0%) |
| Interest Coverage Ratio: -1.31 > 6 (EBITDA TTM 5.14m / Interest Expense TTM 5.65m) |
| A: -0.04 (Total Current Assets 24.3m - Total Current Liabilities 32.5m) / Total Assets 192.0m |
| B: -0.22 (Retained Earnings -43.0m / Total Assets 192.0m) |
| C: -0.04 (EBIT TTM -7.42m / Avg Total Assets 197.6m) |
| D: -0.47 (Book Value of Equity -43.2m / Total Liabilities 91.7m) |
| Altman-Z'' = -1.75 = D |
| DSRI: 0.67 (Receivables 1.97m/3.36m, Revenue 151.8m/172.1m) |
| GMI: 1.05 (GM 60.58% / 63.75%) |
| AQI: 0.99 (AQ_t 0.63 / AQ_t-1 0.63) |
| SGI: 0.88 (Revenue 151.8m / 172.1m) |
| TATA: -0.10 (NI -11.2m - CFO 7.50m) / TA 192.0m) |
| Beneish M = -3.45 (Cap -4..+1) = AA |
As of May 27, 2026, the stock is trading at USD 5.49 with a total of 785,058 shares traded.
Over the past week, the price has changed by +15.34%,
over one month by +124.08%,
over three months by +215.52% and
over the past year by +23.37%.
Airsculpt Technologies has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold AIRS.
- StrongBuy: 0
- Buy: 0
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 4.5 | -18% |
P/S = 2.4764
P/B = 3.7362
Revenue TTM = 151.8m USD
EBIT TTM = -7.42m USD
EBITDA TTM = 5.14m USD
Long Term Debt = 39.4m USD (from longTermDebt, last quarter)
Short Term Debt = 12.6m USD (from shortTermDebt, last quarter)
Debt = 97.2m USD (from shortLongTermDebtTotal, last quarter) + Leases 26.2m
Net Debt = 80.5m USD (calculated: Debt 97.2m - CCE 16.7m)
Enterprise Value = 456.5m USD (376.0m + Debt 97.2m - CCE 16.7m)
Interest Coverage Ratio = -1.31 (Ebit TTM -7.42m / Interest Expense TTM 5.65m)
EV/FCF = 65.74x (Enterprise Value 456.5m / FCF TTM 6.95m)
FCF Yield = 1.52% (FCF TTM 6.95m / Enterprise Value 456.5m)
FCF Margin = 4.57% (FCF TTM 6.95m / Revenue TTM 151.8m)
Net Margin = -7.39% (Net Income TTM -11.2m / Revenue TTM 151.8m)
Gross Margin = 60.58% ((Revenue TTM 151.8m - Cost of Revenue TTM 59.8m) / Revenue TTM)
Gross Margin QoQ = 52.76% (prev 59.11%)
Tobins Q-Ratio = 2.38 (Enterprise Value 456.5m / Total Assets 192.0m)
Interest Expense / Debt = 5.81% (Interest Expense 5.65m / Debt 97.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -5.86m (EBIT -7.42m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.75 (Total Current Assets 24.3m / Total Current Liabilities 32.5m)
Debt / Equity = 0.97 (Debt 97.2m / totalStockholderEquity, last quarter 100.3m)
Debt / EBITDA = 15.67 (Net Debt 80.5m / EBITDA 5.14m)
Debt / FCF = 11.59 (Net Debt 80.5m / FCF TTM 6.95m)
Total Stockholder Equity = 90.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -5.68% (Net Income -11.2m / Total Assets 192.0m)
RoE = -8.42% (Net Income TTM -11.2m / Total Stockholder Equity 133.3m)
RoCE = -4.30% (EBIT -7.42m / Capital Employed (Equity 133.3m + L.T.Debt 39.4m))
RoIC = -3.41% (negative operating profit) (NOPAT -5.86m / Invested Capital 172.2m)
WACC = 15.32% (E(376.0m)/V(473.2m) * Re(18.09%) + D(97.2m)/V(473.2m) * Rd(5.81%) * (1-Tc(0.21)))
Discount Rate = 18.09% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 87.06 | Cagr: 8.86%
[DCF] Terminal Value 55.01% ; FCFF base≈6.95m ; Y1≈6.97m ; Y5≈7.39m
[DCF] Fair Price = N/A (negative equity: EV 52.7m - Net Debt 80.5m = -27.9m; debt exceeds intrinsic value)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.50 | # QB: 0
Revenue Correlation: -86.63 | Revenue CAGR: -8.98% | SUE: 0.08 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.02 | Chg30d=N/A | Revisions=+20% | Analysts=1
EPS next Quarter (2026-09-30): EPS=-0.02 | Chg30d=N/A | Revisions=N/A | Analysts=1
EPS current Year (2026-12-31): EPS=-0.03 | Chg30d=+25.00% | Revisions=-20% | GrowthEPS=+50.0% | GrowthRev=+1.0%
EPS next Year (2027-12-31): EPS=-0.02 | Chg30d=N/A | Revisions=+20% | GrowthEPS=+33.3% | GrowthRev=+2.5%